Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on Jan 27, 2017 5:38am
470 Views
Post# 25762061

RE:When should we expect the remaining IPF results ?

RE:When should we expect the remaining IPF results ? The impression I got from Analyst Day was that the IPF results for the full 40 patients will be reported on sometime in February, probably late February. The results should catalyze partnership discussions especially with Roche if the data show that 4050 in combination with pirfenidone is significantly better than 4050 alone and 4050 in combination with nintedanib (as the animal studies indicate). I would hope that an IPF partnership deal could be struck before the start of the upcoming pivotal trials. With regional partnership deals in Asia, a major partnership deal on IPF and the start of Pg commercial production, PLI should rapidly shift into the next stage of commercial development and put a big smile on the face of all its shareholders.
Bullboard Posts